From generic to biosimilar drugs: why take an innovative pace? by Barei, Fereshteh et al.
21Farmeconomia. Health economics and therapeutic pathways 2012; 13(Suppl 3) © SEEd All rights reserved
purification and processing, formulation and 
packaging). Verifying similarity or compara-
bility of a biosimilar with an innovator pro-
duct therefore requires more than demonstra-
ting bioequivalence, which is sufficient for 
conventional generic versions. The need for 
pharmacovigilance related to the biological 
treatments is an important issue following 
these manufacturing changes [1-3].
To date, the adoption of biosimilars by physi-
cians and patients varies from country to 
country, reflecting local politics of pricing 
and reimbursement, the influence of stakehol-
ders and their attitudes towards their use. 
Currently, Germany and France account for 
half of the biosimilars market value with 34% 
and 17% share, respectively, across Europe, 
although absorption in Spain and the UK has 
also begun to increase [4]. According to Ger-
man IGES institute, the launch of biosimilar 
erythropoietin has allowed insurance funds 
to save €60 million due to price reductions 
in the first 12 months after their entry, the 60 
million came from 2 sources: 40 million from 
originator price cuts and 20 million from bio-
similar price cuts. The pre biosimilar market 
sales were 345M and this fell to 285 hence 
the 60 million is actual savings realized. A 
INTRODUCTION
The changing role of the generic pharma-
ceutical industry has resulted into changes in 
the product portfolio by switching into more 
complex products like biosimilars and bio-
betters. Biosimilars (Europe) or “follow-on” 
biologics (USA) are biological products that 
are similar, but not identical, to an innovator 
product that is already marketed and whose 
patent has expired. Biosimilars cannot be 
considered “generic” equivalents of innova-
tor products as they are not necessarily cli-
nically interchangeable and in some cases 
may exhibit different therapeutic effects. It is 
critical that physicians and pharmacists truly 
understand the complex factors which apply 
to this new and challenging area.
The patent expiry of many biological drugs 
will open the door for greater numbers of 
biosimilar companies to enter the market, but 
marketing approval of biosimilars is a much 
more complicated issue than approval of ge-
neric equivalents. The clinical performance 
of biological treatments is highly dependent 
on the method of production and purification. 
Immunogenicity can be altered with diffe-
rent formulations or different manufacturing 
processes (that is, differences in host cells, 
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ABSTRACT
BACKGROUND: The transition of the generic/biotechnology industry to innovation by investing in innovative R&D will 
enhance business expertise in biopharmaceutical development and manufacturing. The major impact of this evolution is on 
patient access to treatment and savings for the health care systems. OBJECTIVES: The aim of this paper is to investigate 
the innovative aspect of biosimilar and biobetter products, manufactured by some big generic companies. We will also try 
to explore the innovative business strategy, implementing this high risk product differentiation policy. METHODS: This 
qualitative research is conducted by a series of interviews with CEOs, physicians, and academics in different countries. The 
qualitative data obtained were analyzed by Nvivo9.2 software. A literature review has also contributed to our key findings. 
RESULTS: The results show that switching into biosimilars/biobetters is an innovative strategic choice, approved by some 
big generic pharmaceutical companies. The biosimilar/biobetter products can be considered innovative because of their va-
lue added quality. CONCLUSION: Expanding the product portfolio to biosimilars/biobetter can be considered as a long run 
strategy in the innovative business plans aiming to ensure the market access. Patients and their access to better treatments 
are major components of these innovative business models.
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new study commissioned by Sandoz shows 
that, by 2020, eight countries in the European 
Union could save a cumulative total of betwe-
en EUR 11.8 billion and 33.4 billion through 
the use of biosimilar medicines [5].
It is clear that biosimilars will become a ma-
jor part of the biopharmaceutical market and 
will support patient access to pharmacothe-
rapy. However, companies of biosimilar pro-
ducts do not follow the same industrial model 
as that of generic companies. The industrial 
model of classic generic companies is known 
as “copycat maker”, but this model is being 
transformed. Generic pharmaceutical indust-
ry has tried to evolve through changes in their 
business plans and product portfolio with a 
view to maintain a sustainable market place. 
Differentiated products, offering a value-ad-
ded quality, in a market of pharmaceuticals 
facing a lack of radical innovation, play an 
increasingly more prominent role.
The aim of this study is to analyze innovation 
around the development of biosimilars by ge-
neric companies. We will study the case of 
biosimilars from two points of views. First, 
from a viewpoint of relationship between 
generics and biosimilars, why can a switch 
into biosimilars be an attractive prospect? Se-
cond, from an innovative standpoint, are bio-
similars and biobetters innovative products? 
The arrival of generic companies on the 
biosimilar and biobetter market may be the 
beginning of a new model where the phar-
maceutical industry consolidates its presence 
around patient needs. Such a change could 
result in a profound renewal of the entire in-
dustrial chain, promote R&D and boost in-
novation [1,6,7]. By responding to all issues 
affecting the pharmaceutical sector, the chan-
ge of the model, initiated by the new entrants 




In this study, we applied a qualitative ap-
proach. Semi-structured interviews were 
selected because they provide information 
collected during discussions with specialists 
about their views and experiences of recent 
changes. In the absence of research studies 
and documentation on this topic, we decided 
to launch discussions via social networks 
and conducted interviews as well as sending 
questionnaires by email. Until May 2012, 10 
persons with different functions were inter-
viewed in France, Belgium, Korea, Switzer-
land, United States, United Kingdom, and 
India.
Interviews were conducted with managers 
(M), industry consultants (C), lawyers (L), 
researchers (R) and physicians (P). Several 
economic and financial reports from Busi-
ness Insight, Data Monitor, IMS, Ernest & 
Young, Markets and Research were also re-
viewed before and during the interviews. We 
have also participated in forums and confe-
rences in Hungary, France and Germany to 
get up-to-date information. We also partici-
pated in webinars organized by international 
research centers such as Thomson Reuters. 
Discussion groups on the internet that have 
helped us include: Life Science Reimburse-
ment Group, Management Change for Phar-
ma, Biosimilars, Pharmaceutical Intellectual 
Property and Worldwide Generics, Biologics, 
Biosimilars and follow-on R&D. The inter-
view time varied between 30 and 90 minutes.
Data analysis
We have prepared a database of our data col-
lected from interviews. Interviews were re-
corded, transcribed verbatim and analyzed 
using the software NVivo9.2 software accor-
ding to the Matrix Framework approach [8]. 
We used NVivo Dataset and survey to explore 
our findings. In practice, we coded raw data 
at nodes representing themes in our text-data. 
Alternatively, we ran text search query or 
word frequency to identify common subjects 
in survey responses before coding them. Fra-
mework matrices provided a way to conden-
se the source data in a grid. Subsequently, we 
launched questions and found patterns based 
on our coding and checked for coding consi-
stency among interviewees. This method hel-
ped us to compare results and to identify new 
perspectives of the survey results that could 
not be acquired without running the queries 
and coding the results. Our qualitative results 
indicated the main “nodes” in the classifica-
tion results. The main results from the nodes 
are chosen according to our questions about 
the innovative portfolio of generic companies 
and their capacity to switch into biosimilars. 
Several child/sub-nodes relevant to the topic 
have been defined and added. The space co-
vered by each node reflects the frequency of 
that node in our original database.
RESULTS
Figure 1 identifies the five major nodes resul-
ting from the semi-structured interviews. In 
most interviews, the importance of the regu-
latory framework and the marketing strategy 
of the biosimilar industry in management de-
cisions and its impact on the success in the 
pharmaceutical market were mentioned. The 
same general agreement on factors such as 
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“price pressure”, “biosimilar price”, “com-
mercial viability”, “innovative biosimilars”, 
“barriers to entry of biosimilars” and the “im-
portance of strategic marketing and sales for-
ce” has also been observed. Nodes and rela-
tionships between nodes are discussed in 
more detail in the following sections.
From generic to biosimilar, 
a long way between 
imitation and innovation
Biosimilars differ from generic drugs by their 
characteristics, their raw materials and manu-
facturing processes. Differences between ge-
nerics and biosimilars focus both on product 
development, marketing authorisation, and 
post-registration monitoring. Essential diffe-
rences between the two regulatory pathways 
relating to biosimilars and generics are pre-
sented in Table I [9].
The price advantage is the main feature used 
by biosimilar companies to differentiate their 
products. According to survey results for Bu-
siness Insights, «lower prices are a key mar-
keting tool». However, price will not be the 
only way that biosimilars will seek to diffe-
rentiate themselves from reference products. 
For instance, improved formulations and dif-
ferent methods of drug delivery are also very 
important features in the development of bio-
similars (cfr. infra).
While national regulatory authorities in Eu-
rope are responsible for determining sub-
stitution policies, Member States that allow 
substitution of generic drugs generally have 
adopted guidelines that recommend the sub-
stitution between products with the same 
International Nonproprietary Names, and 
which are subject to the underlying princi-
ples of pharmaceutical and biological equi-
valence. However, substitution should not 
apply to drugs derived from biotechnology 
without knowledge and explicit consent of 
the physician. This approach was taken by 
French regulatory authorities. As biosimilars 
are not identical to the reference product, the 
substitution principle cannot automatically 
apply to biosimilars [1,10].
From biosimilar to biobetter, 
an innovative evolution
Biosimilars are new versions of existing 
biopharmaceuticals following patent expiry. 
They are produced using the same core gene-
tic material and are approved on the basis that 
they are comparable to the reference product 
in terms of quality, safety and efficacy. “Bio-
superiors” or “biobetters” refer to a biological 
product that is similar to an already-approved 
biological product, but is also superior in one 
or more product characteristics. Product cha-
Figure 1. Major nodes resulting from qualitative interviews
Generics Biosimilars
Description Chemical origin. 
Same qualitative and 
quantitative composition 
as the active reference
Biological origin. Same 
physico-chemical, biological 




About 3 years About 6-9 years
Development 
cost




processes of generic 
is the same as 
bioavailability
Biosimilar method of 
manufacturing differs from 






Dossier. Data from 
bioequivalence and 
bioavailability
Complete application (Phase 
I and III (IV)). Comparative 
preclinical and clinical data 
in terms of quality, efficacy 




All the indications of 
the originator are also 
indications of generic
Record indication by 
indication, and the need 
for setting up clinical trials 
for each of them if they are 
multiple, but exceptions exist
Substitution Authorized Not authorized
Reimbursement Reimbursement rate 
identical to that of the 
originator
Reimbursement rate identical 
to that of the originator
Commercial 
promotion
Easier to implement and 
less expensive than the 
reference drug
Long and costly, is close to 
that originator
Table I. Differences between regulatory pathways relating to biosimilars and 
generics
racteristics often targeted by biobetter appli-
cants include longer product half-life in the 
body, lower likelihood of aggregation, grea-
ter efficacy, greater purity or fewer adverse 
events [11]. Table II sets out a number of dif-
ferences between biosimilars and biobetters.
An expert in the United States gives the fol-
lowing definition of a biobetter: «As com-
monly used, the term biobetter is applied to 
any follow-on or next-generation product. In 
this respect, many or even the majority of 
marketed biopharmaceuticals are biobetters. 
This includes the vast majority of traditional 
biologics, particularly vaccines and blood/
plasma products. And many follow-on (or ra-
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here. For example, this could include the 
“biobetter” being the absolute same product 
but marketed by a different company holding 
its own full approval and with its labeling in-
cluding an additional or broader indication». 
(C3, USA).
Beside the regulatory problems for biosimi-
lars and biobetters, the patient’s point of view 
remains another challenge:
 - «The concern in the patient’s mind is the 
fear of being prescribed an inferior pro-
duct, especially when this is thought of 
as a cost-saving measure. The more data 
we have to dispel the inferiority theory, 
the more likely we will be successful in 
prescribing biosimilars, so the answer is 
data, data, data» (P1, Oncologist, Michi-
gan).
 - «Is the drug as good as the branded op-
tion? Are there unknown potential side ef-
fects related to poor manufacturing prac-
tices? Where is the drug made? Industry 
could help by assuring the patient of the 
“purity” of their product» (Rheumatolo-
gist, Northwest United States).
 - «They will be concerned about safety and 
efficacy. It will be easier to reassure them 
if each claimed indication for a biosimi-
lar is established through well-performed 
clinical trials. The industry can help by 
sponsoring and supporting these trials». 
(P2 Oncologist, New Jersey) [13].
 - «As for the drugs from the perspective 
of patients, I think biosimilars will be 
just as effective and perhaps even more 
safe (cleaner; use of newer technology). 
Remember that the major entrant to the 
biosimilars market in the USA and Euro-
pe are big players with wealths of expe-
rience» (M4).
Why can biosimilars and biobetters 
be innovative products?
Although the concept of biobetters is just 
emerging, there are certain companies that 
have successfully redesigned existing pro-
ducts to create better biosimilars or biobet-
ters [14]. The innovative value and benefits 
of using biobetters include lower dosage, re-
ther me-too) recombinant proteins would 
now be viewed as “biobetters”, such as the 
multiple follow-on versions of somatropin, 
insulin and Factor VIII biopharmaceuticals. 
Otherwise, historically, many recombinant 
proteins were biobetter versions of human 
tissue-derived protein products which they 
have often replaced» (P3).
Why are biobetters being developed by phar-
maceutical companies? Biobetters allow 
companies to target an established mecha-
nism, safety and efficacy profile, but gene-
rate sales of a new molecular entity and are 
protected by patents. Although development 
costs for biobetters are similar to that of 
a new biological product, chances of suc-
cessful registration are significantly higher. 
This means that the business risk in develo-
ping a biobetter is significantly reduced, and 
the potential for return on investment for a 
company is greatly improved [11,12].
Nevertheless, Table III shows that biobetter 
and biosimilar products which aim to be in-
novative may face several challenges like: 
the uncertainty on financial returns (commer-
cial viability), technical and manufacturing 
problems, a professional approach to mar-
keting and sales force, price differential and 
innovativeness of the product.
Biobetters are value-added biosimilars, but 
this requires clarification as to what “better” 
means? Here, we hear from an American ex-
pert: «I firmly believe that biosimilars can be 
better, that means they are not equal as mar-
gins of tolerance apply, which are commonly 
accepted. The scope of those margins require 
“justification” which I deem is a loophole 
(for the EMA) to assess the product on a case 
by case basis» (M2, June 2012).
Yet, there are very different ideas about bio-
betters, the major problem being in the regu-
latory definition: «In a U.S. regulatory con-
text, biobetter is defined as including (there 
could be other ways of qualifying) the same 
biologic (fully biogeneric, fully identical in 
all active agent and formulation aspects), but 
with something else that is different and that 
is presumed to be an improvement. There is 
no “variant” of a reference product involved 
Price Regulation Approval R&D Marketing Communication
Biosimilar Reduced 
price









marketing and sales 
force, faces aggressive 
lobbying and litigation
Lack of information 
and communication for 




Is a legal 
definition
Lack of clarity Lower R&D 
costs, 12 years of 
market protection
Professional marketing 
and sales force are 
needed



















32.49 33.33 31.77 33.33 33.33 31.4
Biobetter 32.49 33.33 36.45 33.33 33.33 37.2
Table III. Challenges faced by biobetter products
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drug company. This new generation of gene-
ric companies has realized that they have to 
innovate in order to create market space for 
themselves [6].
DISCUSSION
Biosimilars and biobetters are a new business 
opportunity for pharmaceutical companies. 
This business model seems to be driven by 
the lack of innovation in product portfolios, 
price pressure, competition and industrial 
evolution. Our qualitative study has shown 
that investing in the production of biosimi-
lars/biobetters is an innovative approach for 
generic companies. This is because the de-
velopment of biosimilar/biobetter products 
requires advances in scientific and analytic 
techniques that provide greater ability to cha-
racterize and compare complex molecules. 
Also, the product differentiation approach 
seems innovative because these products 
cannot be manufactured without technical, 
scientific, economic and commercial innova-
tion, and because the entry of generic compa-
nies on the biosimilar/biobetter market is li-
kely to stimulate competition and innovation 
dynamics.
Switching to biosimilars/biobetters is not an 
easy, minimum risk strategy but a decision 
that requires considerable technical, scien-
tific and financial investment in a long-term 
perspective. However, it should be noted that 
these products are innovative and that bio-
similars/biobetters can contribute to socie-
ty through cost reduction, better access and 
high-quality treatment. The development of 
the biosimilar/biobetter business is therefore 
a source of growth, providing new sources of 
revenue, margins and opportunities for pro-
duct differentiation.
The transition by the generic/bio-
technology industry to innovation by 
investing in innovative R&D will en-
hance business expertise in biopharma-
ceutical development and manufacturing. 
Even if biosimilars/biobetters are a source of 
innovation, their development is facing seve-
ral challenges: unclear regulatory framewor-
ks, absence of substitution policy, prescriber 
duced side-effects, reduced rate of degrada-
tion in the blood stream and reduced risk of 
immunogenecity. In discussions with Ameri-
cans, the focus is on technical and technolo-
gical innovation:
 - «A longer half-life can be obtained by dif-
ferent conjugation chemistries like pegy-
lations, albumination, Fc conjugation, 
polysialylation, hessylation, hepylation, 
etc. Among different chemistries, pegy-
lation is most common approach cur-
rently used for biobetter development. A 
number of biological drugs developed by 
pegylation of existing biologic molecules 
are available in the market, e.g. pegyla-
ted G-CSF (Neulasta®), pegylated EPO 
(Mircera®), pegylated interferon-α2a (Pe-
gasys®) etc.» (M5)
 - However, the innovative value and be-
nefits of biobetters may come at a price: 
«There might be this misconception that 
reduced R&D costs will translate into 
reduced pricing of drugs, but that is not 
the case. The idea of biobetters is not that 
they are cheaply priced. They cost up to 
120-150 percent of the innovator brands 
unlike biosimilars, which are sold at less 
than 50 percent of the innovator brand 
price» (C5).
 - «A moderately superior biobetter can 
obtain 20-30 percent of market share whe-
reas four biosimilars can probably achieve 
about 50 percent of the market» (M6).
Creating differentiation
Can a biobetter overcome competition from 
biosimilars and establish a niche segment 
for itself? Multinational companies always 
looked at replacing their blockbuster drugs 
once they lost exclusivity. However, during 
the last decade with low innovation rate, the 
industry has seen various innovative business 
models. Similarly, in biologics we have seen 
the growing influence of follow-up drugs 
once a novel biologic loses exclusivity. To 
combat this threat, biobetters are regarded 
as the “game changer” once the originators 
lose patent rights [6,7]. Some generic com-
panies do not merely wish to be a “me too” 
ther me-too) recombinant proteins would 
now be viewed as “biobetters”, such as the 
multiple follow-on versions of somatropin, 
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tissue-derived protein products which they 
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